GLUCOGENOSIS TIPO 1B PDF

Nashicage Hypoglycemia and lactic acidosis can develop after a short fast hours. In the last 30 years, two methods have been used to achieve this goal in young children: For G6PC pathogenic variant p. Without adequate metabolic treatment, patients with GSD I have died in infancy or childhood of overwhelming hypoglycemia and acidosis. Due to potential negative effects 1 sex hormones on hepatic adenomas, combined oral contraception must be avoided in women with GSDI, especially those with adenomas [ Sechi et alAustin et al ].

Author:Dat Tegore
Country:Andorra
Language:English (Spanish)
Genre:Relationship
Published (Last):26 April 2011
Pages:193
PDF File Size:2.49 Mb
ePub File Size:8.22 Mb
ISBN:500-4-65206-862-7
Downloads:41331
Price:Free* [*Free Regsitration Required]
Uploader:Taubei



Bajinn Frequent fractures and radiographic evidence of osteopenia are common. Diet should be low in fructose and sucrose; galactose and lactose intake should be limited to one serving per day; combined oral contraception should be avoided in women, particularly those with adenomas.

The next step is usually a carefully monitored fast. Variants listed in the table have been provided by the authors. Utilizamos cookies para asegurar que damos la mejor experiencia al usuario en nuestro sitio web. Once the G6PC or SLC37A4 pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.

Diagnosis and management of glycogen storage disease type I: Intellectual disability resulting from recurrent, severe hypoglycemia is considered preventable with appropriate treatment. The severity and recurrence of hypoglycemic episodes determines the timing of cornstarch therapy initiation via nasogastric tube or gastrostomy tube in infancy and childhood and oral ingestion in teenagers and adults.

Etiology The disease is due to a dysfunction in the G6P system, a key step in glycemia regulation. Recombinant AAV-directed gene therapy for type I glycogen storage diseases.

Medical nutritional therapy to maintain normal blood glucose levels, prevent hypoglycemia, and provide optimal nutrition for growth and development; allopurinol to prevent gout when dietary therapy fails to completely normalize blood uric acid concentration; lipid-lowering medications for elevated lipid levels despite good metabolic control; citrate supplementation to help prevent development of urinary calculi or ameliorate nephrocalcinosis; angiotensin-converting enzyme ACE inhibitors to treat microalbuminuria; kidney transplantation for end-stage renal disease ESRD ; surgery or other interventions such as percutaneous ethanol injections and radiofrequency ablation for hepatic adenomas; liver transplantation for those individuals refractory to medical treatment; and treatment with human granulocyte colony-stimulating factor G-CSF for recurrent infections.

Although hyperuricemia is present in young affected children, gout rarely develops in untreated children before puberty [ Matern et al ]. Xanthoma and diarrhea may be present. Glycogen also accumulates in kidneys and small intestine. Maintain lipid levels within the normal range to prevent atherosclerosis and pancreatitis. Hypoglycemia and lactic acidosis can develop after a short fast hours. The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a.

Limit galactose and lactose intake to one serving per day. Fasting hypoglycemia is often the most significant problem in GSD I, and typically the problem that leads to the diagnosis.

Glycogen storage disease type I Evaluation of Relatives at Risk Evaluation of sibs of a proband as early as possible allows for prompt diagnosis and treatment with much-improved outcome. Only comments seeking to improve the quality and accuracy of information on glucogenosiss Orphanet website are accepted. Genes and Databases for chromosome locus and glucotenosis.

Uric acid, ketoacids, and free fatty acids further increase the anion gap. However, it is not known if all long-term secondary complications can be avoided by good metabolic control. Medical Nutrition Therapy Goals Maintain normal glucose levels and prevent hypoglycemia: GSDI should be suspected in individuals with the following clinical, laboratory, and histopathologic features.

Many never sleep through the night even in the second year of life. Other therapeutic measures may be needed for associated problems. Untreated affected individuals historically showed delayed onset of puberty; however, with adherence to a strict dietary regimen, age of onset of puberty can be normal [ Sechi et al ].

There is some evidence that metabolic control of the disease is a factor. For those individuals treated with G-CSF serial blood counts should be performed approximately every three months to assess response to treatment and, although the risk of acute myeloid leukemia AML is low, to evaluate for the presence of myeloblasts in the blood.

Signs of hypoglycemia, hepatomegaly, and growth failure Laboratory findings Hypoglycemia. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate. Developmental delay is a potential secondary effect of chronic or recurrent hypoglycemia, but is at least theoretically preventable. Glucogenosis by paula constanaza barria carrillo on Prezi Although hyperuricemia is asymptomatic for years, kidney and joint damage gradually accrue.

Neutropenia is a manifestation of this disease. The disease was named after German doctor Edgar von Gierke. Nighttime intragastric continuous glucose infusion through a nasogastric tube or a gastrostomy tube.

Surveillance of the liver may include the following: Most affected individuals live into adulthood. Related Posts

BOOK DES ECN ROMANA PDF

GLUCOGENOSIS TIPO 1B PDF

Faushura Molecular genetic analysis of 40 patients with glycogen storage disease type Ia: Intellectual disability resulting from recurrent, severe hypoglycemia is glucogenpsis preventable with appropriate treatment. In adults with GSD I, chronic glomerular damage similar to diabetic nephropathy may lead to renal failure. There was a problem providing the content you requested G6P transporter is expressed ubiquitously in tissues such as liver, kidney, large intestine, small intestine, skeletal muscle, and to a lesser extent the brain and heart, unlike G6Pase. Molecular analysis of glycogen storage disease type Ib: Related Genetic Counseling Issues See Management, Evaluation of Relatives at Risk for information on testing at-risk relatives for the purpose of early diagnosis and treatment.

MACLURA TINCTORIA PDF

Enfermedad de Von Gierke

Bajinn Frequent fractures and radiographic evidence of osteopenia are common. Diet should be low in fructose and sucrose; galactose and lactose intake should be limited to one serving per day; combined oral contraception should be avoided in women, particularly those with adenomas. The next step is usually a carefully monitored fast. Variants listed in the table have been provided by the authors. Utilizamos cookies para asegurar que damos la mejor experiencia al usuario en nuestro sitio web. Once the G6PC or SLC37A4 pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible. Diagnosis and management of glycogen storage disease type I: Intellectual disability resulting from recurrent, severe hypoglycemia is considered preventable with appropriate treatment.

GRANDVALIRA MAP PDF

Glucogenosis de tipo 1B

See Molecular Genetics for information on allelic variants detected in this gene. Sequence analysis detects variants that are benign, likely benign, of uncertain significance , likely pathogenic, or pathogenic. For issues to consider in interpretation of sequence analysis results, click here. Methods used may include quantitative PCR , long-range PCR, multiplex ligation-dependent probe amplification MLPA , and a gene -targeted microarray designed to detect single- exon deletions or duplications. The frequency of multi exon deletions is unknown; very few have been reported in either of these genes [ Janecke et al , Wang et al ]. Clinical Characteristics Clinical Description The clinical manifestations of glycogen storage disease type I GSDI are growth retardation leading to short stature and accumulation of glycogen and fat in liver and kidneys resulting in hepatomegaly and renomegaly, respectively [ Kishnani et al ]. Hypoglycemia and lactic acidosis can develop after a short fast hours.

Related Articles